{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:31:18Z","timestamp":1779100278099,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T00:00:00Z","timestamp":1496016000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CHU Ste-Justine Fondation - Fondation des \u00c9toiles"},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00262-017-2022-y","type":"journal-article","created":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T14:18:02Z","timestamp":1496067482000},"page":"1307-1320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["In vitro differentiated plasmacytoid dendritic cells as a tool to induce anti-leukemia activity of natural killer cells"],"prefix":"10.1007","volume":"66","author":[{"given":"Yildian","family":"D\u00edaz-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assila","family":"Belounis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8702-7262","authenticated-orcid":false,"given":"Sabine","family":"Herblot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Duval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,29]]},"reference":[{"key":"2022_CR1","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3389\/fimmu.2015.00578","volume":"6","author":"K Rezvani","year":"2015","unstructured":"Rezvani K, Rouce RH (2015) The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol 6:578. doi: 10.3389\/fimmu.2015.00578","journal-title":"Front Immunol"},{"key":"2022_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1182\/asheducation-2013.1.247","volume":"2013","author":"JS Miller","year":"2013","unstructured":"Miller JS (2013) Therapeutic applications: natural killer cells in the clinic. Hematol Am Soc Hematol Educ Progr 2013:247\u2013253. doi: 10.1182\/asheducation-2013.1.247","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"2022_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fimmu.2011.00018","volume":"2","author":"E Vivier","year":"2011","unstructured":"Vivier E, Ugolini S (2011) Natural killer cells: from basic research to treatments. Front Immunol 2:18. doi: 10.3389\/fimmu.2011.00018","journal-title":"Front Immunol"},{"key":"2022_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/biof.107","volume":"36","author":"NW Zwirner","year":"2010","unstructured":"Zwirner NW, Domaica CI (2010) Cytokine regulation of natural killer cell effector functions. BioFactors 36:274\u2013288. doi: 10.1002\/biof.107","journal-title":"BioFactors"},{"key":"2022_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-014-0026-0","author":"JP Dutcher","year":"2014","unstructured":"Dutcher JP, Schwartzentruber D, Kauffman H, Argarwala S, Tarhini A, Lowder J, Atkins MB (2014) High dose interleukin-2 (Aldesleukin)\u2014expert consensus on best management practices-2014. J Immunother Cancer. doi: 10.1186\/s40425-014-0026-0","journal-title":"J Immunother Cancer"},{"key":"2022_CR6","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMe1110900","volume":"365","author":"JA Bluestone","year":"2011","unstructured":"Bluestone JA (2011) The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med 365:2129\u20132131. doi: 10.1056\/NEJMe1110900","journal-title":"N Engl J Med"},{"key":"2022_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.immuni.2010.08.004","volume":"33","author":"TR Malek","year":"2010","unstructured":"Malek TR, Castro I (2010) Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33:153\u2013165. doi: 10.1016\/j.immuni.2010.08.004","journal-title":"Immunity"},{"key":"2022_CR8","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","volume":"365","author":"J Koreth","year":"2011","unstructured":"Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J, Soiffer RJ (2011) Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 365:2055\u20132066. doi: 10.1056\/NEJMoa1108188","journal-title":"N Engl J Med"},{"key":"2022_CR9","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1182\/blood-2013-05-499970","volume":"123","author":"MT Williams","year":"2014","unstructured":"Williams MT, Yousafzai Y, Cox C, Blair A, Carmody R, Sai S, Chapman KE, McAndrew R, Thomas A, Spence A, Gibson B, Graham GJ, Halsey C (2014) Interleukin-15 enhances cellular proliferation and upregulates CNS homing molecules in pre-B acute lymphoblastic leukemia. Blood 123:3116\u20133127. doi: 10.1182\/blood-2013-05-499970","journal-title":"Blood"},{"key":"2022_CR10","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1200\/JCO.2007.11.8166","volume":"25","author":"G Cario","year":"2007","unstructured":"Cario G, Izraeli S, Teichert A, Rhein P, Skokowa J, Moricke A, Zimmermann M, Schrauder A, Karawajew L, Ludwig WD, Welte K, Schunemann HJ, Schlegelberger B, Schrappe M, Stanulla M (2007) High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. J Clin Oncol 25:4813\u20134820. doi: 10.1200\/JCO.2007.11.8166","journal-title":"J Clin Oncol"},{"key":"2022_CR11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.4049\/jimmunol.174.2.727","volume":"174","author":"F Gerosa","year":"2005","unstructured":"Gerosa F, Gobbi A, Zorzi P, Burg S, Briere F, Carra G, Trinchieri G (2005) The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 174:727\u2013734","journal-title":"J Immunol"},{"key":"2022_CR12","doi-asserted-by":"publisher","first-page":"29440","DOI":"10.18632\/oncotarget.4984","volume":"6","author":"M Lelaidier","year":"2015","unstructured":"Lelaidier M, Diaz-Rodriguez Y, Cordeau M, Cordeiro P, Haddad E, Herblot S, Duval M (2015) TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells. Oncotarget 6:29440\u201329455. doi: 10.18632\/oncotarget.4984","journal-title":"Oncotarget"},{"key":"2022_CR13","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/bmt.2012.176","volume":"48","author":"E Charrier","year":"2013","unstructured":"Charrier E, Cordeiro P, Brito RM, Mezziani S, Herblot S, Le Deist F, Duval M (2013) Reconstitution of maturating and regulatory lymphocyte subsets after cord blood and BMT in children. Bone Marrow Transplant 48:376\u2013382. doi: 10.1038\/bmt.2012.176","journal-title":"Bone Marrow Transplant"},{"key":"2022_CR14","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/leu.2008.343","volume":"23","author":"V Beziat","year":"2009","unstructured":"Beziat V, Nguyen S, Lapusan S, Hervier B, Dhedin N, Bories D, Uzunov M, Boudifa A, Trebeden-Negre H, Norol F, Marjanovic Z, Marie JP, Vernant JP, Debre P, Rio B, Vieillard V (2009) Fully functional NK cells after unrelated cord blood transplantation. Leukemia 23:721\u2013728. doi: 10.1038\/leu.2008.343","journal-title":"Leukemia"},{"key":"2022_CR15","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1182\/blood-2011-04-347070","volume":"118","author":"B Foley","year":"2011","unstructured":"Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, Weisdorf DJ, Miller JS (2011) NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood 118:2784\u20132792. doi: 10.1182\/blood-2011-04-347070","journal-title":"Blood"},{"key":"2022_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bbmt.2007.10.016","volume":"14","author":"P Szabolcs","year":"2008","unstructured":"Szabolcs P, Niedzwiecki D (2008) Immune reconstitution in children after unrelated cord blood transplantation. Biol Blood Marrow Transplant 14:66\u201372. doi: 10.1016\/j.bbmt.2007.10.016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.exphem.2004.11.006","volume":"33","author":"A Romanski","year":"2005","unstructured":"Romanski A, Bug G, Becker S, Kampfmann M, Seifried E, Hoelzer D, Ottmann OG, Tonn T (2005) Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol 33:344\u2013352. doi: 10.1016\/j.exphem.2004.11.006","journal-title":"Exp Hematol"},{"key":"2022_CR18","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.3324\/haematol.2013.101931","volume":"99","author":"GF Torelli","year":"2014","unstructured":"Torelli GF, Peragine N, Raponi S, Pagliara D, De Propris MS, Vitale A, Bertaina A, Barberi W, Moretta L, Basso G, Santoni A, Guarini A, Locatelli F, Foa R (2014) Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. Haematologica 99:1248\u20131254. doi: 10.3324\/haematol.2013.101931","journal-title":"Haematologica"},{"key":"2022_CR19","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.bbmt.2014.06.007","volume":"20","author":"E Charrier","year":"2014","unstructured":"Charrier E, Cordeiro P, Brito RM, Harnois M, Mezziani S, Herblot S, Le Deist F, Duval M (2014) Impaired interferon-alpha production by plasmacytoid dendritic cells after cord blood transplantation in children: implication for post-transplantation toll-like receptor ligand-based immunotherapy. Biol Blood Marrow Transplant 20:1501\u20131507. doi: 10.1016\/j.bbmt.2014.06.007","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022_CR20","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1182\/blood-2003-09-3058","volume":"103","author":"W Chen","year":"2004","unstructured":"Chen W, Antonenko S, Sederstrom JM, Liang X, Chan AS, Kanzler H, Blom B, Blazar BR, Liu YJ (2004) Thrombopoietin cooperates with FLT3-ligand in the generation of plasmacytoid dendritic cell precursors from human hematopoietic progenitors. Blood 103:2547\u20132553. doi: 10.1182\/blood-2003-09-3058","journal-title":"Blood"},{"key":"2022_CR21","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1089\/scd.2013.0521","volume":"23","author":"S Thordardottir","year":"2014","unstructured":"Thordardottir S, Hangalapura BN, Hutten T, Cossu M, Spanholtz J, Schaap N, Radstake TR, van der Voort R, Dolstra H (2014) The aryl hydrocarbon receptor antagonist StemRegenin 1 promotes human plasmacytoid and myeloid dendritic cell development from CD34+ hematopoietic progenitor cells. Stem Cells Dev 23:955\u2013967. doi: 10.1089\/scd.2013.0521","journal-title":"Stem Cells Dev"},{"key":"2022_CR22","doi-asserted-by":"publisher","first-page":"e1004556","DOI":"10.1371\/journal.ppat.1004556","volume":"10","author":"A Egli","year":"2014","unstructured":"Egli A, Santer DM, O\u2019Shea D, Barakat K, Syedbasha M, Vollmer M, Baluch A, Bhat R, Groenendyk J, Joyce MA, Lisboa LF, Thomas BS, Battegay M, Khanna N, Mueller T, Tyrrell DL, Houghton M, Humar A, Kumar D (2014) IL-28B is a key regulator of B- and T-cell vaccine responses against influenza. PLoS Pathog 10:e1004556. doi: 10.1371\/journal.ppat.1004556","journal-title":"PLoS Pathog"},{"key":"2022_CR23","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-12-2357","volume":"73","author":"W Xu","year":"2013","unstructured":"Xu W, Jones M, Liu B, Zhu X, Johnson CB, Edwards AC, Kong L, Jeng EK, Han K, Marcus WD, Rubinstein MP, Rhode PR, Wong HC (2013) Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu\/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res 73:3075\u20133086. doi: 10.1158\/0008-5472.CAN-12-2357","journal-title":"Cancer Res"},{"key":"2022_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.cellimm.2012.04.010","volume":"276","author":"E Charrier","year":"2012","unstructured":"Charrier E, Cordeiro P, Cordeau M, Dardari R, Michaud A, Harnois M, Merindol N, Herblot S, Duval M (2012) Post-transcriptional down-regulation of Toll-like receptor signaling pathway in umbilical cord blood plasmacytoid dendritic cells. Cell Immunol 276:114\u2013121. doi: 10.1016\/j.cellimm.2012.04.010","journal-title":"Cell Immunol"},{"key":"2022_CR25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/icb.2013.65","volume":"92","author":"H Liu","year":"2014","unstructured":"Liu H, Ramachandran I, Gabrilovich DI (2014) Regulation of plasmacytoid dendritic cell development in mice by aryl hydrocarbon receptor. Immunol Cell Biol 92:200\u2013203. doi: 10.1038\/icb.2013.65","journal-title":"Immunol Cell Biol"},{"key":"2022_CR26","doi-asserted-by":"publisher","first-page":"49259","DOI":"10.18632\/oncotarget.10272","volume":"7","author":"A Lasfar","year":"2016","unstructured":"Lasfar A, de laTorre A, Abushahba W, Cohen-Solal KA, Castaneda I, Yuan Y, Reuhl K, Zloza A, Raveche E, Laskin DL, Kotenko SV (2016) Concerted action of IFN-alpha and IFN-lambda induces local NK cell immunity and halts cancer growth. Oncotarget 7:49259\u201349267. doi: 10.18632\/oncotarget.10272","journal-title":"Oncotarget"},{"key":"2022_CR27","doi-asserted-by":"publisher","first-page":"E2376","DOI":"10.1073\/pnas.1424241112","volume":"112","author":"F Souza-Fonseca-Guimaraes","year":"2015","unstructured":"Souza-Fonseca-Guimaraes F, Young A, Mittal D, Martinet L, Bruedigam C, Takeda K, Andoniou CE, Degli-Esposti MA, Hill GR, Smyth MJ (2015) NK cells require IL-28R for optimal in vivo activity. Proc Natl Acad Sci USA 112:E2376\u2013E2384. doi: 10.1073\/pnas.1424241112","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022_CR28","doi-asserted-by":"publisher","first-page":"19960","DOI":"10.18632\/oncotarget.4758","volume":"6","author":"F Souza-Fonseca-Guimaraes","year":"2015","unstructured":"Souza-Fonseca-Guimaraes F, Young A, Smyth MJ (2015) IFN type III: in vivo NK cell response. Oncotarget 6:19960\u201319961. doi: 10.18632\/oncotarget.4758","journal-title":"Oncotarget"},{"key":"2022_CR29","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.immuni.2013.04.006","volume":"38","author":"N Onai","year":"2013","unstructured":"Onai N, Kurabayashi K, Hosoi-Amaike M, Toyama-Sorimachi N, Matsushima K, Inaba K, Ohteki T (2013) A clonogenic progenitor with prominent plasmacytoid dendritic cell developmental potential. Immunity 38:943\u2013957. doi: 10.1016\/j.immuni.2013.04.006","journal-title":"Immunity"},{"key":"2022_CR30","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood.V95.11.3489","volume":"95","author":"HJ McKenna","year":"2000","unstructured":"McKenna HJ, Stocking KL, Miller RE, Brasel K, De Smedt T, Maraskovsky E, Maliszewski CR, Lynch DH, Smith J, Pulendran B, Roux ER, Teepe M, Lyman SD, Peschon JJ (2000) Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95:3489\u20133497","journal-title":"Blood"},{"key":"2022_CR31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/ni.1615","volume":"9","author":"C Waskow","year":"2008","unstructured":"Waskow C, Liu K, Darrasse-Jeze G, Guermonprez P, Ginhoux F, Merad M, Shengelia T, Yao K, Nussenzweig M (2008) The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol 9:676\u2013683. doi: 10.1038\/ni.1615","journal-title":"Nat Immunol"},{"key":"2022_CR32","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.V96.3.878","volume":"96","author":"E Maraskovsky","year":"2000","unstructured":"Maraskovsky E, Daro E, Roux E, Teepe M, Maliszewski CR, Hoek J, Caron D, Lebsack ME, McKenna HJ (2000) In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 96:878\u2013884","journal-title":"Blood"},{"key":"2022_CR33","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4049\/jimmunol.165.1.566","volume":"165","author":"B Pulendran","year":"2000","unstructured":"Pulendran B, Banchereau J, Burkeholder S, Kraus E, Guinet E, Chalouni C, Caron D, Maliszewski C, Davoust J, Fay J, Palucka K (2000) Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol 165:566\u2013572","journal-title":"J Immunol"},{"key":"2022_CR34","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1084\/jem.192.12.1785","volume":"192","author":"B Blom","year":"2000","unstructured":"Blom B, Ho S, Antonenko S, Liu YJ (2000) Generation of interferon alpha-producing predendritic cell (Pre-DC)2 from human CD34(+) hematopoietic stem cells. J Exp Med 192:1785\u20131796","journal-title":"J Exp Med"},{"key":"2022_CR35","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1191536","volume":"329","author":"AE Boitano","year":"2010","unstructured":"Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE, Sutton SE, Walker JR, Flaveny CA, Perdew GH, Denison MS, Schultz PG, Cooke MP (2010) Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329:1345\u20131348. doi: 10.1126\/science.1191536","journal-title":"Science"},{"key":"2022_CR36","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"S Reagan-Shaw","year":"2008","unstructured":"Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659\u2013661. doi: 10.1096\/fj.07-9574LSF","journal-title":"FASEB J"},{"key":"2022_CR37","unstructured":"Administration USDoHaHSFaD (2005) Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm078932.pdf . Accessed May 2016"},{"key":"2022_CR38","doi-asserted-by":"publisher","first-page":"557","DOI":"10.4161\/cbt.24598","volume":"14","author":"CP Belani","year":"2013","unstructured":"Belani CP, Nemunaitis JJ, Chachoua A, Eisenberg PD, Raez LE, Cuevas JD, Mather CB, Benner RJ, Meech SJ (2013) Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer. Cancer Biol Ther 14:557\u2013563. doi: 10.4161\/cbt.24598","journal-title":"Cancer Biol Ther"},{"key":"2022_CR39","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ajh.23460","volume":"88","author":"TE Witzig","year":"2013","unstructured":"Witzig TE, Wiseman GA, Maurer MJ, Habermann TM, Micallef IN, Nowakowski GS, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Link BK, Zent CS, Johnston PB, Shanafelt TD, Allmer C, Asmann YW, Gupta M, Ballas ZK, Smith BJ, Weiner GJ (2013) A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. Am J Hematol 88:589\u2013593. doi: 10.1002\/ajh.23460","journal-title":"Am J Hematol"},{"key":"2022_CR40","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.4049\/jimmunol.170.9.4465","volume":"170","author":"M Kerkmann","year":"2003","unstructured":"Kerkmann M, Rothenfusser S, Hornung V, Towarowski A, Wagner M, Sarris A, Giese T, Endres S, Hartmann G (2003) Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol 170:4465\u20134474","journal-title":"J Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-017-2022-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2022-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2022-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T21:02:13Z","timestamp":1602190933000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-017-2022-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,29]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["2022"],"URL":"https:\/\/doi.org\/10.1007\/s00262-017-2022-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,29]]}}}